Tempus AI, Inc. has agreed to acquire genomics company Personalis, Inc. in an all-stock transaction valuing the cancer-testing firm at roughly $1.5 billion, deepening its push to build an end-to-end, AI-driven precision oncology platform. The definitive agreement, announced on July 20, 2026, offers Personalis shareholders $16.25 per share, with Tempus holding an option to pay up to 50% of the consideration in cash.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.